Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.40 - $27.20
Previous CloseN/A
Volume201.32K
Average Volume (3M)835.76K
Market Cap
$1.18B
Enterprise Value$1.03B
Total Cash (Recent Filing)$209.35K
Total Debt (Recent Filing)$697.06K
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 07, 2025EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.77
Shares Outstanding81,484,950
10 Day Avg. Volume752,809
30 Day Avg. Volume835,756
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4117.42
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.41K
Enterprise Value/Ebitda-3.87
Forecast
1Y Price Target
$41.11Price Target Upside204.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Viridian Therapeutics News
PremiumCompany Announcements
Viridian Therapeutics Enters New $300M Sale Agreement
PremiumCompany Announcements
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
PremiumCompany Announcements
Viridian Therapeutics Reports Strong Progress and Financials
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive topline results from the Phase 3 THRIVE-2 study of lead asset veligrotug in chronic thyroid eye disease, demonstrating differentiated efficacy data that build on the successful Phase 3 THRIVE study.
Financial StabilityViridian’s cash and short-term investments stood at $717.6M, which is expected to provide sufficient operating runway into the second half of 2027.
Market PositionGiven that Tepezza is now a ~$1.9B product in the US, veligrotug is positioned to rapidly capture significant share in the TED market.
Bears Say
Market CompetitionUnlike the TED market, where Viridian has been able to demonstrate differentiated efficacy, the FcRn market is considerably more crowded with a number of large competitors.
---
Ownership Overview
4.26% Insiders
25.94% Mutual Funds
56.32% Other Institutional Investors
1.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $11.40 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $1.18B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 36 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$1.035 by $0.225.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.97.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 81,484,950 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$0.81 in its last earnings report, beating expectations of -$1.035. Following the earnings report the stock price went down -1.545%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
---
Viridian Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.11 (204.97% Upside)
$41.11 (204.97% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.53%
12-Months-Change
Fundamentals
Return on Equity
-45.77%
Trailing 12-Months
Asset Growth
51.38%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
---
VRDN Stock 12 Month Forecast
Average Price Target
$41.11
▲(204.97% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Regeneron
―
Ultragenyx Pharmaceutical
―
Argenx Se
―
Immunovant
―
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
16/39 ratings generated profit
1 Year Average Return
-3.92%
reiterated a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 41.03% of your transactions generating a profit, with an average return of -3.92% per trade.
---